Jeffrey Bird
Managing Director at Bluebird Ventures
Palo Alto, California
Overview
Work Experience
Managing Director
2019 - Current
Bluebird Ventures is an early-stage Life Sciences venture fund.
Limited Partner
2021
Managing Director
2002
Board Member
2022
Investor
2022
Therapeutics company developing broad antiviral therapy for influenza, Coronavirus and other respiratory pathogens
Investor
2020
Diagnostic company developing tests for MRD in lymphoma and solid tumors. Series A with Stanford founders.
Investor
2020
Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
Raised $600,500,000.00 from Patient Square Capital, CAM Capital, Alumni Ventures, Narya Capital, Bluebird Ventures, JDRF T1D Fund, QVT Financial, Transhuman Capital, Lightswitch Capital and Dexcel Pharma.
Investor
2020
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Raised $240,998,000.00 from ARCH Venture Partners.
Investor and Board Member
2019
Epirium Bio is a biopharmaceutical company developing a small molecule platform targeting improvements in muscle strength.
Raised $86,392,000.00 from ARCH Venture Partners, Longitude Capital, Adams Street Partners, Bluebird Ventures, Vertex Ventures HC and The Longevity Fund.
Investor and Board Member
2019
Investor
2016
Grail is a healthcare company that develops pan-cancer screening tests designed to detect cancers at an early stage.
Raised $2,004,655,040.00 from CPP Investments, Huangpu River Capital, Illumina and PSP Investments.
Education
MD
1982 - 1988
Bachelor of Science (BS)
1978 - 1982